Author

Gabriel Paiva da Silva Lima

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Sex differences in lipid management among high-risk patients without prior myocardial infarction or stroke: results from the VESALIUS-REAL global study

Effective lipid-lowering therapy (LLT) reduces the risk of cardiovascular outcomes in patients at high cardiovascular risk, as well as in those without a history of myocardial infarction (MI) or stroke. The VESALIUS-CV trial demonstrated the benefit of intensive low-density lipoprotein cholesterol (LDL-C) lowerin...

Q. Chan, J. Cegla, J. Cornel et al. · European Heart Journal · 0 citations

Open access Oct 2026

Lipid management in patients with coronary artery disease at risk of a first major atherosclerotic cardiovascular event: findings from the VESALIUS-REAL global study

In this large, global, real-world study, most patients with CAD at risk of a first MACE were undertreated with LLT and did not achieve recommended LDL-C levels, highlighting substantial gaps between guideline recommendations and real-world practice.

Q. Chan, J. Cegla, J. Cornel et al. · European Heart Journal · 0 citations

Open access Aug 2026

Effects of Evolocumab on Mortality Outcomes in Patients Without Previous Myocardial Infarction or Stroke: A Prespecified Analysis of the VESALIUS-CV Randomized Clinical Trial.

These results support using evolocumab to improve survival in high-risk patients who have not experienced a previous myocardial infarction or stroke, including those with high-risk diabetes without qualifying atherosclerosis with low-density lipoprotein-cholesterol ≥ 90 mg/dl or apolipoprotein B ≥ 80 mg/dl.

Robert P. Giugliano, E. Bohula, A. Bellavia et al. · Circulation · 0 citations